Authors:

Liese Barbier, MSc, PharmD, PhD, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

Catarina Lopes Pereira, MSc, PharmD, Chair, ISPOR Biosimilar Special Interest Group, Brussels, Belgium

Teresa Barcina Lacosta, MSc, PharmD, PhD Candidate, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

Contributors:

Aurelio Arias, MSc, IQVIA, Zurich, Switzerland

Sue Caleo-Naeyaert, MCom, PharmD, Independent consultant, Health Economics, Global Market Access, and Pricing, New South Wales, Australia

Dalia Dawoud, MSc, PhD, National Institute for Health and Care Excellence (NICE), London, UK; Cairo University, Faculty of Pharmacy, Cairo, Egypt

András Inotai, PharmD, PhD, Semmelweis University, Center for Health Technology Assessment, Budapest, Hungary

Manthan Janodia, MPH, PhD, Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India 

Patel Jayeshkumar, Alexion Pharmaceuticals, Inc., Connecticut, USA

Chia Jie, University of Utah College of Pharmacy, Utah, USA

Amir Nazari, Novartis Oncology, Tehran Province, Iran

Chaudhari Vivek, PhD, EMD Serono, Inc., Massachusetts, USA

John Whalen, BS, BSc, MBA, Pharming Group N.V., London, UK

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×